Project Grant HT94252510664
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$610K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $388,194 to The Johns Hopkins University to conduct research on "The Aging Microenvironment as a Driver of Pancreatic Cancer Metastasis." The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical solutions for critical health challenges. The 3-year project, running from...
This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...
The Johns Hopkins University will receive $620,588 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research to develop a 3D multiscale analysis of malignant progression in human pancreatic cancer. Through September 2025, researchers will investigate medical solutions for pancreatic cancer at the cellular and tissue levels to transform understanding and treatment of this...
This federal Project Grant award of $360,413.00, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University focused on early hepatic dissemination of pancreatic cancer. The research aims to evaluate the efficacy of systemic chemotherapy-enhanced alpha-particle radiotherapy as a treatment approach. The award has a performance period from November 1, 2024 to October 31, 2027. As a leading academic...
The U.S. Defense Health Agency awarded a $776,831 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University to conduct research on P2 purinergic receptors in pancreatic ductal adenocarcinoma as potential therapeutic targets. The grant, which runs from August 1, 2025 to July 31, 2028, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. As a leading...
This $835,531 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund a research project at The Johns Hopkins University to develop a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The project aims to transform healthcare for military service members and the broader...
This federal Project Grant award of $336,257.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV MMR-P pancreatic ductal adenocarcinoma. The 3-year award, which runs from September 1, 2024 to August 31, 2027, is granted to The Johns Hopkins University, a private non-profit research institution...
The federal Project Grant award of $714,934.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) was awarded to the Henry Ford Health System in Detroit, Michigan to conduct research on "Finding the Missing Link Between Pancreatic Neoplasia and Carcinoma." The award has a performance period from July 1, 2025 to June 30, 2028. The Military Medical Research and Development program supports advanced biomedical research aimed at transforming...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...